Announcements
- Molecular Partners Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533’s Proposed Mechanism of Action
- Life Science Cares Launches in Switzerland
- Molecular Partners Announces All Board Proposals Approved at the Annual General Meeting
- Molecular Partners Publishes Invitation to Annual General Meeting 2024
- Molecular Partners Reports Corporate Highlights From Q4 2023 and Key Financials for Full Year 2023
- Molecular Partners Announces Dismissal of Class Action Lawsuit
- Molecular Partners To Hold Conference Call to Discuss Fourth Quarter and Full Year 2023 Results and Announces Upcoming Investor Presentations
- Molecular Partners Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at ASH Annual Meeting
More ▼
Key statistics
As of last trade Molecular Partners AG (6ML0:DUS) traded at 3.20, 7.38% above its 52-week low of 2.98, set on Apr 22, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.20 |
---|---|
High | 3.20 |
Low | 3.20 |
Bid | 3.20 |
Offer | 3.52 |
Previous close | 3.68 |
Average volume | 0.00 |
---|---|
Shares outstanding | 36.37m |
Free float | 32.85m |
P/E (TTM) | -- |
Market cap | 134.57m USD |
EPS (TTM) | -2.09 USD |
Data delayed at least 15 minutes, as of May 07 2024 08:10 BST.
More ▼